Financhill
Buy
57

ZBH Quote, Financials, Valuation and Earnings

Last price:
$104.86
Seasonality move :
0.28%
Day range:
$102.86 - $105.10
52-week range:
$97.69 - $133.90
Dividend yield:
0.92%
P/E ratio:
23.56x
P/S ratio:
2.78x
P/B ratio:
1.67x
Volume:
2.1M
Avg. volume:
2M
1-year change:
-18.32%
Market cap:
$20.9B
Revenue:
$7.7B
EPS (TTM):
$4.45

Analysts' Opinion

  • Consensus Rating
    Zimmer Biomet Holdings has received a consensus rating of Hold. The company's average rating is a Hold based on 6 Buy ratings, 17 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $121.85, Zimmer Biomet Holdings has an estimated upside of 16.24% from its current price of $104.83.
  • Price Target Downside
    According to analysts, the lowest downside price target is $105.00 representing 100% downside risk from its current price of $104.83.

Fair Value

  • According to the consensus of 24 analysts, Zimmer Biomet Holdings has 16.24% upside to fair value with a price target of $121.85 per share.

ZBH vs. S&P 500

  • Over the past 5 trading days, Zimmer Biomet Holdings has overperformed the S&P 500 by 6.7% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Zimmer Biomet Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Zimmer Biomet Holdings has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Zimmer Biomet Holdings reported revenues of $2B.

Earnings Growth

  • Zimmer Biomet Holdings earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Zimmer Biomet Holdings reported earnings per share of $1.20.
Enterprise value:
26.5B
EV / Invested capital:
1.42x
Price / LTM sales:
2.78x
EV / EBIT:
21.16x
EV / Revenue:
3.46x
PEG ratio (5yr expected):
0.15x
EV / Free cash flow:
23.23x
Price / Operating cash flow:
18.70x
Enterprise value / EBITDA:
11.79x
Gross Profit (TTM):
$5.5B
Return On Assets:
4.2%
Net Income Margin (TTM):
11.77%
Return On Equity:
7.21%
Return On Invested Capital:
4.87%
Operating Margin:
20.94%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $6.9B $7.4B $7.7B $1.9B $2B
Gross Profit $4.9B $5.3B $5.5B $1.4B $1.4B
Operating Income $1.2B $1.5B $1.5B $420.8M $423.6M
EBITDA $1.5B $2.2B $2.3B $576M $614.5M
Diluted EPS $1.10 $4.89 $4.45 $2.01 $1.20
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $5.1B $4.9B $4.4B $4.6B $4.7B
Total Assets $24.4B $23.5B $21.1B $21.5B $21.4B
Current Liabilities $2.6B $3.5B $2.4B $2.9B $2.5B
Total Liabilities $12.2B $10.8B $9B $9B $8.9B
Total Equity $12.2B $12.7B $12B $12.5B $12.5B
Total Debt $8.1B $7.1B $5.7B $5.8B $6.2B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $1.3B $1.6B $1.5B $588.4M $506.3M
Cash From Investing -$529.2M -$778.9M -$888.1M -$220.8M -$291.2M
Cash From Financing -$843.8M -$763.5M -$484.5M -$251.4M -$240.6M
Free Cash Flow $1.1B $1.2B $1.1B $537.6M $421.4M
ZBH
Sector
Market Cap
$20.9B
$43.6M
Price % of 52-Week High
78.29%
47.61%
Dividend Yield
0.92%
0%
Shareholder Yield
4.35%
-0.67%
1-Year Price Total Return
-18.33%
-34.6%
Beta (5-Year)
1.022
0.747
Dividend yield:
0.92%
Annualized payout:
$0.96
Payout ratio:
21.69%
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $101.55
200-day SMA
Sell
Level $109.01
Bollinger Bands (100)
Sell
Level 103.5 - 110.12
Chaikin Money Flow
Buy
Level 274.3M
20-day SMA
Sell
Level $105.35
Relative Strength Index (RSI14)
Buy
Level 50.28
ADX Line
Sell
Level 29.24
Williams %R
Neutral
Level -36.25
50-day SMA
Sell
Level $106.13
MACD (12, 26)
Sell
Level -1.38
25-day Aroon Oscillator
Sell
Level -44
On Balance Volume
Sell
Level -1.2M

Financial Scores

Hold
Altman Z-Score (Annual)
Level (2.9793)
Buy
CA Score (Annual)
Level (0.3158)
Buy
Beneish M-Score (Annual)
Level (-2.594)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-1.6448)
Buy
Piotroski F Score (Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (7)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Stock Forecast FAQ

In the current month, ZBH has received 6 Buy ratings 17 Hold ratings, and 1 Sell ratings. The ZBH average analyst price target in the past 3 months is $121.85.

  • Where Will Zimmer Biomet Holdings Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Zimmer Biomet Holdings share price will rise to $121.85 per share over the next 12 months.

  • What Do Analysts Say About Zimmer Biomet Holdings?

    Analysts are divided on their view about Zimmer Biomet Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zimmer Biomet Holdings is a Sell and believe this share price will drop from its current level to $105.00.

  • What Is Zimmer Biomet Holdings's Price Target?

    The price target for Zimmer Biomet Holdings over the next 1-year time period is forecast to be $121.85 according to 24 Wall Street analysts, 6 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.

  • Is ZBH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Zimmer Biomet Holdings is a Hold. 17 of 24 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of ZBH?

    You can purchase shares of Zimmer Biomet Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zimmer Biomet Holdings shares.

  • What Is The Zimmer Biomet Holdings Share Price Today?

    Zimmer Biomet Holdings was last trading at $104.86 per share. This represents the most recent stock quote for Zimmer Biomet Holdings. Yesterday, Zimmer Biomet Holdings closed at $104.83 per share.

  • How To Buy Zimmer Biomet Holdings Stock Online?

    In order to purchase Zimmer Biomet Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Walmart Stock Fall?
Why Did Walmart Stock Fall?

Walmart (NYSE:WMT) tumbled in spite of strong Q4 results that…

Is Cadence Stock a Buy, Sell or Hold?
Is Cadence Stock a Buy, Sell or Hold?

Cadence Design Systems (NASDAQ:CDNS) has seen its stock move sharply…

Is PFE the Best Dividend Play in Its Industry?
Is PFE the Best Dividend Play in Its Industry?

By their inherent nature, established pharma companies face a demand…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Sell
48
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Sell
2
GLOB alert for Feb 22

Globant SA [GLOB] is down 27.81% over the past day.

Sell
42
CELH alert for Feb 22

Celsius Holdings [CELH] is up 27.77% over the past day.

Buy
60
HIMS alert for Feb 22

Hims & Hers Health [HIMS] is down 25.64% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock